Appleton Partners Inc. MA Lowers Position in AbbVie Inc. $ABBV

Appleton Partners Inc. MA decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 11.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,177 shares of the company’s stock after selling 4,274 shares during the quarter. Appleton Partners Inc. MA’s holdings in AbbVie were worth $7,809,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. bought a new position in shares of AbbVie during the 2nd quarter valued at about $26,000. Chelsea Counsel Co. bought a new stake in shares of AbbVie in the third quarter worth about $26,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter worth about $31,000. Caitlin John LLC purchased a new stake in shares of AbbVie in the third quarter worth about $33,000. Finally, Delos Wealth Advisors LLC bought a new position in AbbVie during the second quarter valued at approximately $39,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Down 0.1%

Shares of ABBV opened at $204.89 on Tuesday. The firm has a market capitalization of $362.29 billion, a P/E ratio of 86.82, a P/E/G ratio of 0.71 and a beta of 0.34. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a fifty day moving average price of $222.79 and a 200-day moving average price of $224.80.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the firm posted $2.16 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Analyst Ratings Changes

A number of research firms have issued reports on ABBV. HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Royal Bank Of Canada assumed coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. Evercore reduced their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.08% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.